NCT01228669 - Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 25, 2010

Primary Completion Date

September 10, 2012

Study Completion Date

September 10, 2012

Conditions

Congenital Bleeding DisorderHaemophilia AHaemophilia BHealthy

Interventions

DRUG

NNC 0172-0000-2021

Single dose injected i.v. (into a vein). Each treatment dose is assessed for safety before escalating to next dose

DRUG

NNC 0172-0000-2021

Single dose injected s.c. (under the skin). Each treatment dose is assessed for safety before escalating to next dose.

DRUG

placebo

Single dose injected i.v. and s.c. Each treatment dose is assessed for safety before escalating to next dose.

Trial Locations (16)

1090

Novo Nordisk Investigational Site, Vienna

2100

Novo Nordisk Investigational Site, Copenhagen

8091

Novo Nordisk Investigational Site, Zurich

10249

Novo Nordisk Investigational Site, Berlin

10400

Novo Nordisk Investigational Site, Bangkok

20124

Novo Nordisk Investigational Site, Milan

28046

Novo Nordisk Investigational Site, Madrid

50400

Novo Nordisk Investigational Site, Kuala Lumpur

60590

Novo Nordisk Investigational Site, Frankfurt/M.

0699

Novo Nordisk Investigational Site, Polokwane

205 02

Novo Nordisk Investigational Site, Malmo

HA1 3UJ

Novo Nordisk Investigational Site, Harrow

NW3 2QG

Novo Nordisk Investigational Site, London

SE1 7EH

Novo Nordisk Investigational Site, London

W12 0NN

Novo Nordisk Investigational Site, London

M13 9WL

Novo Nordisk Investigational Site, Manchester